Literature DB >> 15512962

Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium.

Banmeet S Anand1, Suresh Katragadda, Yasser E Nashed, Ashim K Mitra.   

Abstract

PURPOSE: The aim of this study was to explore the feasibility of improvement of ocular bioavailability of the antiviral agent acyclovir by designing amino acid prodrugs targeted to the amino acid transporters on the rabbit cornea.
MATERIALS AND METHODS: Transcorneal flux of two water-soluble amino acid ester prodrugs of acyclovir (ACV), gamma-glutamate-ACV (EACV) and L-tyrosine-ACV (YACV), was studied across freshly excised rabbit cornea. Chemical and enzymatic hydrolysis studies of the two prodrugs were also conducted.
RESULTS: EACV inhibited the uptake of [(3)H]L-Arg in rabbit primary corneal epithelial cells (rPCECs). The compound also exhibited longer half-life (t(1/2)) in cornea in comparison to YACV. Transcorneal flux of EACV was observed to be concentration-, energy-, and sodium-dependent and independent of pH within the range studied. EACV transport was inhibited by neutral and cationic amino acids, L-ornithine (specific for cationic amino acids), and BCH (2-aminobicyclo-[2,2,1]-heptane-2-carboxylic-acid) (specific inhibitor for L-type system and B(0,+) system). On the other hand, YACV was not recognized by this amino acid transporter as it failed to inhibit the uptake of [(3)H]Arg, and also its transport across cornea was not inhibited by arginine. YACV and EACV exhibited excellent antiviral activity against HSV-1 and 2 and Varicella-Zoster Virus (VZV) in comparison to ACV.
CONCLUSIONS: Analyses of the inhibition pattern of EACV transport suggests the involvement of a single transport system; namely, B(0,+). Design of amino acid prodrugs seems to be an attractive strategy to enhance the solubility of the otherwise poorly aqueous soluble compounds and also to afford a targeted and possibly enhanced delivery of the active drug.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15512962     DOI: 10.1080/02713680490504614

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  16 in total

Review 1.  Ocular drug delivery.

Authors:  Ripal Gaudana; Hari Krishna Ananthula; Ashwin Parenky; Ashim K Mitra
Journal:  AAPS J       Date:  2010-05-01       Impact factor: 4.009

Review 2.  Prodrug strategies in ocular drug delivery.

Authors:  Megha Barot; Mahuya Bagui; Mitan R Gokulgandhi; Ashim K Mitra
Journal:  Med Chem       Date:  2012-07       Impact factor: 2.745

Review 3.  A comprehensive insight on ocular pharmacokinetics.

Authors:  Vibhuti Agrahari; Abhirup Mandal; Vivek Agrahari; Hoang M Trinh; Mary Joseph; Animikh Ray; Hicheme Hadji; Ranjana Mitra; Dhananjay Pal; Ashim K Mitra
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

4.  Synthesis and in vitro stability of amino acid prodrugs of 6-β-naltrexol for microneedle-enhanced transdermal delivery.

Authors:  Joshua A Eldridge; Mikolaj Milewski; Audra L Stinchcomb; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2014-10-02       Impact factor: 2.823

5.  Prodrug approach to improve absorption of prednisolone.

Authors:  Ye Sheng; Xiaoyan Yang; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2015-04-15       Impact factor: 5.875

6.  Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors.

Authors:  Sherifa Hasabelnaby; Ayman Goudah; Hitesh K Agarwal; Mosaad S M abd Alla; Werner Tjarks
Journal:  Eur J Med Chem       Date:  2012-07-27       Impact factor: 6.514

7.  Transporter targeted gatifloxacin prodrugs: synthesis, permeability, and topical ocular delivery.

Authors:  Sunil K Vooturi; Rajendra S Kadam; Uday B Kompella
Journal:  Mol Pharm       Date:  2012-10-11       Impact factor: 4.939

8.  Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections.

Authors:  Suresh Katragadda; Sriram Gunda; Sudharshan Hariharan; Ashim K Mitra
Journal:  Int J Pharm       Date:  2008-03-22       Impact factor: 5.875

9.  Transcorneal permeation of L- and D-aspartate ester prodrugs of acyclovir: delineation of passive diffusion versus transporter involvement.

Authors:  Soumyajit Majumdar; Tushar Hingorani; Ramesh Srirangam; Rama Sarma Gadepalli; John M Rimoldi; Michael A Repka
Journal:  Pharm Res       Date:  2008-10-07       Impact factor: 4.200

10.  Pharmacokinetics of amino acid ester prodrugs of acyclovir after oral administration: interaction with the transporters on Caco-2 cells.

Authors:  Suresh Katragadda; Ritesh Jain; Deep Kwatra; Sudharshan Hariharan; Ashim K Mitra
Journal:  Int J Pharm       Date:  2008-06-27       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.